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Summary
Objectives: A new, pharmacokinetically enhanced, oral formulation of amoxicillin/
clavulanic acid has been developed to overcome resistance in the major bacterial
respiratory pathogen Streptococcus pneumoniae, while maintaining excellent activ-
ity against Haemophilus influenzae and Moraxella catarrhalis, including beta-lacta-
mase producing strains. This study was conducted to provide in vitro susceptibility
data for amoxicillin/clavulanic acid and 16 comparator agents against the key
respiratory tract pathogens.influenzae;
Moraxella catarrhalis Methods: Susceptibility testing was performed on 9172 isolates collected from 95
centers in North America, Europe, Australia, and Hong Kong by broth microdilution
MIC determination, according to NCCLS methods, using amoxicillin/clavulanic acid
and 16 comparator antimicrobial agents. Results were interpreted according to NCCLS
breakpoints and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints based on
oral dosing regimens.* Corresponding author. Tel.: +1 440 835 4458;
fax: +1 440 835 5786.
E-mail address: amdlmk@aol.com (L.M. Koeth).
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According to the World Health Organization Global
Burden of Disease assessment, lower respiratory
infections are the fourth highest cause of mortality
in developed regions, accounting for 324,000 or
3.5% of all deaths in 1990, and the leading cause
of mortality in developing regions, accounting for
3,915,000 or 9.9% of all deaths.1 The 1999 WHO
estimate of worldwide deaths due to all respiratory
infections was 4,039,000, with the majority again
being in the developing world. Recent data from the
USA identify acute respiratory infection as the
seventh highest cause of death, with 62,034 deaths
attributed to pneumonia in 2001.2
The most commonly reported bacterial patho-
gen in acute respiratory infections is consistently
Streptococcus pneumoniae3—5 found in 20—60% of
patients with community-acquired pneumonia
(CAP) and 20—43% of patients with acute sinusitis.6
In a recent meta-analysis of CAP in 33,148 patients
in 127 studies, 86% of deaths (1019 of 1187) among
patients with identifiable pathogens were in
patients with Streptococcus pneumoniae infec-
tions.7
Haemophilus influenzae is the most common
cause of acute exacerbations of chronic bronchitis
(AECB)8 and is also identified in 3—10% of CAP. Other,
less common though nonetheless serious con-
tributors to respiratory disease include Moraxella
catarrhalis (1—2%) and Legionella pneumophila
(1—6%).9,10
Streptococcus pyogenes, themost frequent cause
of severe pharyngitis and exudative tonsillitis, and
an occasional cause of severe invasive infections,
contributes significant morbidity in both adults and
children. Rheumatic fever, a complication of S.
pyogenes infection, is infrequent in the developed
world, but is still a significant problem in the devel-oping world, occurring most frequently in the age
group 3—15 years.10
Several drugs have shown excellent activity
against antimicrobial-resistant S. pneumoniae,
including amoxicillin, amoxicillin/clavulanic acid,
and the newer fluoroquinolones.11,12 While fluoro-
quinolones are an important part of the antimicro-
bial armamentarium, their overuse has resulted in
the development and spread of resistance to these
agents in many species such as staphylococci and
Enterobacteriaceae. Amoxicillin/clavulanic acid
was developed to enhance the activity of amoxicillin
against b-lactamase-producing bacteria, by the
addition of the b-lactamase inhibitor, clavulanic
acid. This agent has been used for more than 15
years as an oral antimicrobial agent and has main-
tained in vitro activity against the major respiratory
tract pathogens. A new formulation of amoxicillin/
clavulanic acid has recently been developed with an
enhanced pharmacokinetic profile which extends
the time the plasma drug concentration exceeds
the MICs of pathogens (T > MIC) in the serum. Each
tablet consists of a layer of immediate-release
amoxicillin trihydrate plus clavulanic acid and a
layer of sustained-release amoxicillin sodium. It
has been shown that, for beta-lactams, a plasma
T > MIC for 40% of the dosing interval correlates
with high rates of bacteriological cure.13 Pharma-
cokinetically-enhanced amoxicillin/clavulanic acid
provides plasma amoxicillin levels above 4 mg/mL
(amoxicillin component) for 49% of the dosing inter-
val, and therefore should be able to eradicate
pathogens, including many penicillin-resistant
strains, with MICs of 4 mg/mL (amoxicillin compo-
nent).14
Because of difficulty in obtaining adequate speci-
mens and the time involved in laboratory culture
and antimicrobial susceptibility determination,
most acute respiratory infections are treatedResults: Overall, 93.5% of Streptococcus pneumoniae isolates were susceptible to
amoxicillin/clavulanic acid at the current susceptible breakpoint of 2 mg/mL and
97.3% at the PK/PD susceptible breakpoint of 4 mg/mL for the extended release
formulation. Proportions of isolates that were penicillin intermediate and resistant
were 13% and 16.5%, respectively, while 25% were macrolide resistant and 21.8%
trimethoprim/sulfamethoxazole resistant. 21.9% of Haemophilus influenzae were b-
lactamase producers and 16.8% trimethoprim/sulfamethoxazole resistant, >99% of
isolates were susceptible to amoxicillin/clavulanic acid, cefixime, ciprofloxacin and
levofloxacin at NCCLS breakpoints. The most active agents against Moraxella catar-
rhalis were amoxicillin/clavulanic acid, macrolides, cefixime, fluoroquinolones, and
doxycycline. Overall, 13% of Streptococcus pyogenes were resistant to macrolides.
Conclusion: The extended release formulation of amoxicillin/clavulanic acid has
potential for empiric use against many respiratory tract infections worldwide due
to its activity against species resistant to many agents currently in use.
# 2004 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
364 L.M. Koeth et al.empirically, with adjustments to treatment based
both on clinical response and as specific laboratory
data become available.15 For this reason it is impor-
tant for the clinician to know the local prevalence of
resistance so that empiric choices of antibiotics can
be made rationally.
This study was conducted to provide in vitro
susceptibility data for amoxicillin/clavulanic acid
and 17 comparator agents against the key respira-
tory tract pathogens, Streptococcus pneumoniae,
Haemophilus influenzae,Moraxella catarrhalis, and
Streptococcus pyogenes.Methods and materials
Isolates were collected from 89 centers within the
USA, Australia, Canada, Hong Kong, Mexico, Bel-
gium, France, Germany, Italy, the Netherlands,
Spain, Sweden, and the United Kingdom. Most cen-
ters were large hospitals located in major cities
within each country.
Strains included in the study were isolated from
cultures of blood, sputum, bronchoalveolar lavage
(BAL), middle ear fluid, nasopharyngeal swabs or
aspirates, paranasal sinuses, and throat specimens
(Streptococcus pyogenes only) between May 1999
and December 2000. Patients from whom isolates
were recovered had been diagnosed with commu-
nity-acquired respiratory tract infections (RTI) and
were outpatients or hospitalized patients within
48 hours of admission. All RTI isolates were sub-
mitted as they were recovered (i.e. not a sampling
of only certain strains). Isolates recovered from
patients with nosocomially-acquired infections, or
cystic fibrosis disease were excluded from the study.
Isolates from patients of all ages were accepted.
Isolates were submitted to two testing sites for
centralized testing, and the identification of each
isolate was confirmed following standard proce-
dures.16
Susceptibility testing was conducted by broth
microdilution MIC determination, according to
NCCLS recommended procedures,17 using custom
dried microdilution trays (TREK, Westlake, OH).
All testing was carried out at Laboratory Specialists
Inc., Westlake, OH or Case Western Reserve Uni-
versity, Cleveland, OH, except for UK strains, which
were tested at GR Micro Ltd., London.
The following antimicrobial agents were tested:
amoxicillin/clavulanic acid (2:1 ratio), ampicillin,
amoxicillin, azithromycin, cefaclor, cefixime, cef-
prozil, ceftriaxone, cefuroxime axetil, ciprofloxa-
cin, clarithromycin, clindamycin, doxycycline,
erythromycin, levofloxacin, penicillin and trimetho-
prim/sulfamethoxazole (1:19 ratio). The microdilu-tion trays were reconstituted with isolates
suspended in Haemophilus Test Medium (HTM) broth
(PML, Tualatin, OR) (H. influenzae), cation-adjusted
Mueller Hinton broth supplemented with 3% lysed
horse blood (CAMHB-LHB) (MicroScan, Sacramento,
CA) (S. pneumoniae and S. pyogenes), or cation-
adjusted Mueller Hinton broth (CAMHB) (MicroScan)
(M. catarrhalis). For each isolate, a suspension
equivalent to a 0.5 McFarland Standard was pre-
pared in saline and aliquots added to the broth.
Viable counts were made by the laboratories at the
commencement of the study to determine the
volume of the 0.5 McFarland organism suspension
to be added to the broth to produce an inoculum size
of 3—7  105 cfu/ml for each species. In addition,
inoculum counts were determined for each isolate
during testing to assure that the inocula were within
the acceptable range. Trays were inoculated using
an autoinoculator (TREK) to deliver 100 ml/well,
incubated under ambient conditions at 35 8C for
20—24 hours, and the lowest concentration showing
no growth read as the MIC.
Quality-control organisms specified by NCCLS,
including S. pneumoniae ATCC 49619, H. influenzae
ATCC strains 49247 and 49766, S. aureus ATCC 29213
and E. coli ATCC strains 25922 and 35218 were
tested on each day of testing. In addition to the
NCCLS recommended strains, a set of 50 isolates
each of S. pneumoniae and H. influenzae from
frozen stocks which represented a wide range of
resistance profiles were used to test each new lot of
dried microdilution trays. This testing showed that
the trays of all lots used provided reproducible
results.
Data analysis
MIC50’s, MIC90’s, and the proportion of isolates of
each species that were susceptible were deter-
mined for the agents tested, based on NCCLS18
and/or pharmacokinetic/pharmacodynamic (PK/
PD) interpretive criteria. PK/PD breakpoints were
based on standard dosing regimens and criteria
appropriate to each agent for respiratory tract
infections.13,19—26 For b-lactams, erythromycin
and clarithromycin, these breakpoints were based
on free drug concentrations in serum present for
40—50% of the dosing interval, while for azithromy-
cin, the fluoroquinolones, and doxycycline, they
were based on 24-hour unbound serum AUC/MIC
ratio of 25 to 30 (Tables 1 and 2). Based on these
criteria, a susceptible breakpoint of 4/2 mg/mL
was used to represent the pharmacokinetically
enhanced formulation of amoxicillin/clavulanic
acid for all species tested.
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Table 1 Cumulative MIC frequency distribution, MIC50 and MIC90 values, and susceptibility of Streptococcus pneumoniae (n = 3714).
Agent Susceptible
breakpoint
Cumulative percentage of isolates inhibited at MIC (in mg/mL)
indicated belowa
MIC50
(mg/mL)
MIC90
(mg/mL)
% Sb
PK/PD NCCLS 0.015 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16 32 64
Penicillin — 0.06 43.7c 65.5 70.5 74.7 78.3 80.3 83.5 92.2 99.4 100 100d 0.03 2 70.5%
Amoxicillin/clavulanic acid
(current formulation)
2/1 2/1 4.0c 64.6 72.5 75.8 79.1 80.6 84.3 93.5 97.3 99.3 100d 0.03/0.015 2/1 93.5%
Amoxicillin/clavulanic acid
(enhanced formulation)
4/2 4/2 4.0c 64.6 72.5 75.8 79.1 80.6 84.3 93.5 97.3 99.3 100d 0.03/0.015 2/1 97.5%
Amoxicillin 2 2 5.5c 64.5 72.6 75.6 78.6 80.3 84.2 93.8 97.3 99.2 100d 0.03 2 93.8%
Cefaclor 0.5 1 10.6c 47.8 72.3 78.4 80.3 81.5d 2 32 47.8%
Cefixime 1 — 0.3c 4.4 57.3 68.7 73.7d 0.25 2 70.5%
Cefprozil 1 2 31.6c 68.6 76.3 79.0 81.0 82.6 87.9 96.8d 0.25 16 81.0%
Ceftriaxone — 0.5 26.7c 65.1 72.7 76.5 79.9 83.7 95.0 99.1 99.8 99.9 100 100 100d 0.03 1 95.0%
Cefuroxime axetil 1 1 1.9c 38.6 63.9 69.0 73.9 77.6 79.5 81.4 87.5 97.8 99.3d 0.06 8 79.5%
Azithromycin 0.12 0.5 0.5c 5.1 58.9 72.8 73.7 74.0 74.5 76.3 79.7 83.2 84.3 84.5d 0.06 64 74.0%
Clarithromycin 0.25 0.25 6.2c 66.8 73.0 73.6 73.9 74.4 75.4 78.9 81.5 84.1 84.7 85.0d 0.03 64 73.9%
Erythromycin 0.25 0.25 1.3c 23.2 71.6 73.2 73.6 74.0 74.4 76.4 79.8 83.2 84.5 84.9d 0.06 64 73.6%
Clindamycin — 0.25 0.7c 6.1 62.0 83.9 84.6 85.0 85.4d 0.06 2 84.6%
Levofloxacin 2 2 0.1c 0.1 0.1 0.1 0.7 41.8 96.7 99.0 99.2 99.4d 1 1 99.0%
Doxycycline 0.25 — 8.0c 44.6 76.7 78.9 79.6 80.5 84.1 93.8d 0.25 8 76.7%
Trimethoprim/
sulfamethoxazole
— 0.5/9.5 0.2c 2.6 30.0 62.4 68.3 73.7 78.2 90.7 98.2 99.6 99.8d 0.25/4.75 4/76 68.3%
a NCCLS intermediate values shown in boldface; MIC values for amoxicillin/clavulanic acid are shown as amoxicillin component; MIC values for trimethoprim/sulfamethoxazole are shown
as trimethoprim component.
b Percentage susceptible at NCCLS susceptible breakpoint, except for enhanced amoxicillin/clavulanic acid and doxycycline which are based on PK/PD breakpoints, and cefixime which is
based on penicillin susceptibility.
c Lowest concentration tested.
d Highest concentration tested.
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Table 2 MIC50, MIC90 (mg/mL) and percent susceptibility values
a of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pyogenes.
Antimicrobial agents PK/PD BP H. influenzae (n = 3793) M. catarrhalis (n = 972) S. pyogenes (n = 693)
NCCLS
BP
MIC50/MIC90 %S
NCCLS
%S
PK/PD
MIC50/MIC90 %S
NCCLS
%S
PK/PD
NCCLS BP MIC50/MIC90 %S
NCCLS
%S
PK/PD
Amoxicillin/clavulanic acidb
(current formulation)
2 4 0.5/1 99.8 98.7 0.12/0.25 — 100 — 0.015/0.03 — 100
Amoxicillin/clavulanic acidb
(enhanced formulation)
4 — 0.5/1 — 99.8 0.12/0.25 — 100 — 0.015/0.03 — 100
Amoxicillin 2 — 0.5/32 — 79 4/16 — 33.3 — 0.015/0.03 — 100
Ampicillin NA 1 0.25/32 78.8 — 4/16 — — 0.25 0.12/0.12 100 —
Penicillin NA — — — — — — — 0.12 0.015/0.015 100 —
Cefaclor 0.5 8 4/8 90.7 2.1 2/4 — 14.6 — 0.5/0.5 — 91.9
Cefiximec 1 1 0.06/0.06 99.7 99.7 0.25/0.5 — 99.6 — 0.12/0.12 — 99.3
Cefprozil 1 8 2/8 92.7 21.9 2/8 — 20.4 — 0.12/0.12 — 100
Ceftriaxoned 1 2 0.015/0.015 99.9 99.9 0.25/1 — 95.6 0.5 0.015/0.03 100 100
Cefuroxime axetile 1 4 1/2 97.9 77.1 1/4 — 52.4 — 0.015/0.03 — 100
Azithromycin 0.12 4 1/2 99.7 1.9 0.03/0.03 — 98.2 0.5 0.12/4 86.7 84
Clarithromycin 0.25 8 8/8 90 0.6 0.06/0.12 — 98.2 0.25 0.03/4 86.7 86.7
Erythromycin 0.25 — 4/8 — 0.8 0.12/0.25 — 96.1 0.25 0.06/8 87.1 87.1
Clindamycin — NA — — — — — — 0.25 0.06/0.12 97.1 —
Ciprofloxacin 1 1 0.008/0.015 99.9 99.9 0.03/0.06 — 100 — — — —
Levofloxacin 2 2 0.015/0.015 99.9 99.9 0.03/0.06 — 100 2 0.5/1 100 100
Doxycycline 0.25 — 0.5/1 — 30.8 0.25/0.25 — 93.9 0.12/8 — 85.3
Trimethoprim/
sulfamethoxazolef
0.5 0.5 0.12/8 83.2 — 0.25/1 — 81.2 0.12/1 — 63.6
BP = Breakpoint; NA = not applicable; — = no breakpoint available or not tested; S = susceptible; I = intermediate.
a Breakpoints used to interpret MICs in this study, based on NCCLS and PK/PD breakpoints.13,19—26. Values shown are susceptible breakpoints in mg/mL. Isolates with MICs above the
breakpoints shown were regarded as resistant.
b Amoxicillin/clavulanic acid is expressed in terms of amoxicillin. Susceptibility interpretations based on the new amoxicillin/clavulanic acid 2000/125 mg PK/PD breakpoints of 4S/8I/
16R.
c S. pneumoniae susceptibility of cefixime is based on susceptibility to penicillin.
d Breakpoints used for non-meningeal infections; breakpoints for meningitis are S, 0.5 mg/mL; I1 mg/mL, R > 2 mg/mL.
e Breakpoints used for cefuroxime axetil, breakpoints for cefuroxime sodium are S  0.5 mg/mL, I1 mg/mL, R > 2 mg/mL.
f Trimethoprim/sulfamethoxazole is expressed in terms of trimethoprim.
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.Results
There were a total of 3714 S. pneumoniae, 3793 H.
influenzae, 972 M. catarrhalis, and 693 S. pyogenes
tested. The overall S. pneumoniae penicillin sus-
ceptibility distribution was 70.5% susceptible, 13%
intermediate and 16.5% resistant (Table 1), with
country-specific distribution shown in Table 3.
b-Lactamase was produced by 20.6% of the
H. influenzae and 93.5% of M. catarrhalis isolates.
MIC50 and MIC90 for all species tested and the pro-
portion of isolates of S. pneumoniae, H. influenzae,
M. catarrhalis, and S. pyogenes susceptible to
the antimicrobial agents tested are shown in Tables
1 and 2. The amoxicillin/clavulanic acid MIC50/90’s
(expressed in terms of the amoxicillin component in
mg/mL) were: S. pneumoniae 0.03/2, H. influenzae
0.5/1, M. catarrhalis 0.12/0.25, and S. pyogenes
0.015/0.03. At the current amoxicillin/clavulanic
acid susceptible PK/PD breakpoint of 2 mg/mL
(amoxicillin component), 93.5% of S. pneumoniae,
98.7% of H. influenzae, 100% of M. catarrhalis and
S. pyogenes were susceptible. At the susceptible
PK/PD breakpoint of 4 mg/mL (amoxicillin compo-
nent) for the enhanced amoxicillin/clavulanic
acid formulation 97.3% of S. pneumoniae, 99.8%
of H. influenzae, and 100% of M. catarrhalis and
S. pyogenes, were susceptible.
The prevalence of resistance in S. pneumoniae to
selected agents and of b-lactamase production and
trimethoprim/sulfamethoxazole resistance in H.
influenzae, varied around the world (Table 3 and
Figure 1). Five countries (France, Hong Kong, Mex-
ico, Spain and the USA) had a prevalence of peni-
cillin-resistant S. pneumoniae of >20%, while the
Netherlands, Sweden, the UK and Germany had the
lowest prevalences, at less than 5%. The highest
prevalences (greater than 29%) of b-lactamase pro-
duction by H. influenzae were in France, Hong Kong
and the USA. The countries with the lowest preva-
lence (less than 5%) were Italy, the Netherlands, and
Germany. The percentage of b-lactamase-negative,
ampicillin-resistant (BLNAR) H. influenzae strains
was 0.18%. Of the seven BLNAR isolates found in
this study, five were recovered in Italy. Spain and
Mexico had the highest prevalence of trimethoprim/
sulfamethoxazole-resistant H. influenzae (>30%).
Amoxicillin/clavulanic acid susceptibility rates
for S. pneumoniae, based on the NCCLS breakpoint
for the current amoxicillin/clavulanic acid formula-
tion, differed among countries from >99% suscep-
tible in the Netherlands, Germany, Sweden, and the
United Kingdom, to lows of 81.4% in Hong Kong,
81.7% in Spain, and 85.3% in the USA. All other
countries were over 92% (Table 3). At the PK/PD
breakpoint of 4 mg/mL (amoxicillin component) for
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Figure 1 Distribution of b-lactamase-positive and trimethoprim-sulfamethoxazole-resistant Haemophilus influenzae
by country.the extended release amoxicillin/clavulanic acid
formulation, >97.6% of isolates were susceptible
in all countries except for Spain (93.8%) and the
USA (90.4%).
Thirty-seven isolates of S. pneumoniae had levo-
floxacin MICs of 4 mg/mL; the highest percentage
of these were from Hong Kong, where 10.8% of
isolates had MICs >8 mg/mL for levofloxacin. World-
wide, the prevalence of levofloxacin resistance was
0.75%, with three countries (Australia, Italy, and
Sweden) having 0% and six countries (Belgium,
France, Germany, the Netherlands, Spain and the
United Kingdom) with prevalences of below 1%.
Among these 37 resistant strains, many remained
susceptible to several other agents including peni-
cillin, clindamycin, and erythromycin. Hong Kong
was the exception, with ten of 11 strains resistant to
penicillin, four of 11 resistant to clindamycin, and
ten of 11 levofloxacin-resistant strains being resis-
tant to erythromycin.
In vitro activity against S. pneumoniae, based on
the proportion of isolates susceptible (according to
current NCCLS breakpoints and PK/PD breakpoints
for agents without NCCLS breakpoints), from most
active to least active, was: levofloxacin, amoxicil-
lin/clavulanic acid (enhanced formulation), cef-
triaxone, amoxicillin/clavulanic acid (current
formulation), and amoxicillin, all with activity
greater than 90%. Clindamycin, cefprozil, cefurox-
ime axetil, doxycycline, azithromycin, clarithromy-
cin, erythromycin, cefixime, trimethoprim/
sulfamethoxazole, all showed activity from 85% to
68%, while cefaclor was at 47.8% (Table 1).
When S. pneumoniae was classified by penicillin
susceptibility category, cross-resistance with
macrolides, azithromycin, doxycycline, and tri-
methoprim/sulfamethoxazole was noted (Table 5).For other b-lactam agents (except cefaclor), >98%
of penicillin-susceptible isolates were susceptible,
while 64% were susceptible to cefaclor at the NCCLS
breakpoint. b-Lactam susceptibility of penicillin-
intermediate isolates varied, with >98% of isolates
being susceptible to amoxicillin, amoxicillin-clavu-
lanic acid (all formulations) and ceftriaxone, 60—
70% to cefprozil and cefuroxime axetil, and<20% to
cefaclor. b-Lactam susceptibility of penicillin-resis-
tant isolates varied, with 83.3% of isolates being
susceptible to amoxicillin-clavulanic acid
(enhanced formulation), 70.9% to ceftriaxone,
60—62% to amoxicillin and amoxicillin-clavulanic
acid (current formulation), and <2% to cefprozil,
cefuroxime axetil and cefaclor. Levofloxacin (at
97.5%) and enhanced formulation amoxicillin/cla-
vulanic acid (83.5%) showed the best activity against
penicillin-resistant strains of S. pneumoniae (Table
4). These data were further analyzed by country for
cross-resistance between penicillin and the other
classes of agents (Table 5).
Since susceptibility to other b-lactam agents in
each country largely followed the pattern of sus-
ceptibility by penicillin category shown above,
these agents are not shown in Table 5. The macro-
lides, clindamycin, and doxycycline were generally
active (84% susceptible) against penicillin-suscep-
tible strains in most countries examined, except for
France, Hong Kong, Italy, and Belgium. Trimetho-
prim/sulfamethoxazole activity was 83% suscep-
tible in all countries except Australia (77.9%), Hong
Kong (76.3%), Italy (60.1%), Mexico (71.8%) and
Spain (79.4%). Resistance to all classes of agent
generally increased with increasing penicillin resis-
tance. France, with the lowest penicillin suscept-
ibility (23% intermediate, 40% resistant) also had
low macrolide susceptibility, even for penicillin-
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Table 4 Susceptibility of Streptococcus pneumoniae to agents tested by penicillin susceptibility status.
Antimicrobial agent % Susceptible
Penicillin susceptible
(n = 2,618)
Penicillin intermediate
(n = 484)
Penicillin resistant
(n = 612)
Amoxicillin/clavulanic acid
(current formulation)
100 100 60.3
Amoxicillin/clavulanic acid
(enhanced formulation)
100 100 83.5
Amoxicillin 100 100 62.4
Cefaclor 14.5/64.4a 2.5/17.8a 0.2/0.3a
Cefixime 98.1 34.9 0.3
Cefprozil 99.3 66.5 1.8
Ceftriaxone 100 98.6 70.9
Cefuroxime axetil 99.8 69.2 1.0
Azithromycin 87.6 48.1 29.2
Clarithromycin 88.6 50.2 29.6
Erythromycin 88.3 49.6 29.6
Clindamycin 93.8 69.6 56.7
Levofloxacin 99.2 99.6 97.5b
Doxycycline 88.7 55.2 42.0
Trimethoprim/sulfamethoxazole 85.6 47.5 10.6
Susceptible PK/PD breakpoints used except for cefaclor, whichwas interpreted by PK/PD and NCCLS breakpoints, and cefixime, which
was interpreted by PK/PD breakpoint.
a Susceptibility at susceptible PK/PD / NCCLS breakpoints.
b Therewere 15 levofloxacin-resistant isolates in this group, whichwere isolated in Belgium (1 isolate), France (1), Hong Kong (10),
Mexico (1), Spain (1), and the USA (1).susceptible strains (66.4%), with decreasing sus-
ceptibility for penicillin-intermediate and -resistant
strains (25.4% and 17.1%, respectively). Clindamy-
cin, doxycycline, and trimethoprim/sulfamethoxa-
zole also showed low susceptibility in French
penicillin-resistant strains (19.7%, 40.2%, and
17.9% respectively). Hong Kong strains, with the
highest penicillin resistance (56.9%), had low sus-
ceptibility to all of the agent classes (<10%), except
for clindamycin, where 77.6% were susceptible.
In vitro activity against H. influenzae, based on
the proportion of isolates susceptible (according to
PK/PD breakpoints), from most active to least
active, was: levofloxacin, ciprofloxacin, ceftriax-
one, amoxicillin/clavulanic acid (enhanced formu-
lation), cefixime, amoxicillin/clavulanic acid
(current formulation), all with activity greater than
98%; amoxicillin, cefuroxime axetil, doxycycline,
and cefprozil, ranging from 79%—22%; and cefaclor,
azithromycin, erythromycin, and clarithromycin, at
less than 3% (Table 2). While there was considerable
variation in b-lactamase production and suscept-
ibility to ampicillin, amoxicillin and trimetho-
prim/sulfamethoxazole between isolates from
different countries (Figure 1), there was little var-
iation in susceptibility between countries for other
agents. There was no association noted between
b-lactamase production and resistance to trimetho-
prim/sulfamethoxazole in any country.All M. catarrhalis isolates were susceptible
(according to PK/PD breakpoints; there are no
NCCLS breakpoints for this species) to amoxicillin/
clavulanic acid (both formulations), ciprofloxacin,
and levofloxacin (Table 2). b-Lactamase was pro-
duced by 93% of isolates. The in vitro activity of
other agents against M. catarrhalis, based on pro-
portion of isolates susceptible, from most active to
least active, was cefixime, azithromycin, clarithro-
mycin, erythromycin, ceftriaxone, and doxycycline,
all with activity greater than 93%, and cefuroxime
axetil, amoxicillin, cefprozil, and cefaclor, ranging
from 52%—15%. There was little variation in suscept-
ibility between countries for all agents.
No resistance to amoxicillin/clavulanic acid,
amoxicillin, ampicillin, penicillin, ceftriaxone, cef-
prozil, cefuroxime axetil, and levofloxacin was seen
in S. pyogenes. The in vitro activity of other agents
against S. pyogenes, based on proportion of isolates
susceptible (according to current NCCLS break-
points and PK/PD breakpoints for agents without
NCCLS breakpoints), from most to least active, was:
cefixime, clindamycin, cefaclor, all over 90%, and
erythromycin, clarithromycin, azithromycin, and
doxycycline, which were all above 84% (Table 2).
The susceptibility of S. pyogenes from the USA,
Canada, the UK, Australia, and the Netherlands to
macrolides was 90% or greater (represented by ery-
thromycin in Figure 2), while Italy had the lowest
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Table 5 Susceptibility of Streptococcus pneumoniae to selected classes of antimicrobial agents by country, based on penicillin susceptibility.
Penicillin susceptible Penicillin intermediate Penicillin resistant
n Agent class n Agent class n Agent class
Erythromy-
cina
Clindamy-
cin
Doxycycl-
ine
TMP/SMXb Erythromy-
cina
Clindamy-
cin
Doxycycl-
ine
TMP/SMXb Erythromy-
cina
Clindamy-
cin
Doxycycl-
ine
TMP/SMXb
Australia 113 89.4 99.1 87.6 77.9 27 88.9 88.9 77.8 59.3 16 25 50 37.5 25
Belgium 190 71.6 78.9 75.1 83.7 32 68.8 96.9 62.5 62.5 22 31.8 40.9 40.9 9.1
Canada 238 91.6 96.6 98.7 83.6 32 71.9 96.9 62.5 62.5 24 33.3 79.2 54.2 12.5
France 108 66.4 82.2 80.6 87.0 67 25.4 38.8 40.3 44.8 117 17.1 19.7 40.2 17.9
Germany 274 88.7 94.9 91.2 89.1 24 58.3 58.3 58.3 62.5 5 80 80 80 20
Hong Kong 38 60.5 73.7 42.1 76.3 6 0 33.3 16.7 16.7 58 3.4 77.6 6.9 3.4
Italy 213 69.5 79.3 75.6 60.1 34 23.5 67.6 58.8 55.9 29 24.1 34.5 48.3 3.4
Mexico 124 93.5 96.0 84.7 71.8 100 44 80 53 26 57 47.4 70.2 35.1 7.0
Netherlands 285 96.5 97.9 91.6 97.9 10 90 100 90 80 5 60 60 40 20
Spain 126 90.5 94.4 90.5 79.4 37 32.4 32.4 24.3 32.4 77 51.9 53.2 37.7 7.8
Sweden 246 95.1 99.6 96.3 95.9 32 84.4 93.8 78.1 62.5 12 50 50 58.3 8.3
United Kingdom 277 93.5 98.9 96.0 94.9 9 33.3 33.3 22.2 77.8 13 69.2 76.9 76.9 0
USA 386 92.7 99.2 93.5 86.3 85 58.8 85.9 69.5 49.4 177 23.7 72.9 52.0 10.7
a Values for erythromycin used; values for azithromycin and clarithromycin are similar.
b TMP/SMX = trimethoprim/sulfamethoxazole.
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Figure 2 Distribution of erythromycin resistance in Streptococcus pyogenes by country.susceptibility (56.2%). The macrolide susceptibility
of S. pyogenes from all other countries (with the
exception of Hong Kong, where strains of this spe-
cies were not collected) ranged between 76.6% and
89.4%. The susceptibility of clindamycin was 100% in
all countries except France (88.2%), Italy, Belgium,
the USA and Germany (92.2—98%).Discussion
Several recent and ongoing surveillance studies
have tracked the increasing prevalence of antibiotic
resistance around the world. The prevalence of
penicillin-resistant S. pneumoniae recently repor-
ted by country, ranged from less than 5% to nearly
70%.27—30 The prevalence of b-lactamase production
by H. influenzae has been reported as low as 4% in
Russia to a high of 30% in the USA.29,30
In this study, large differences in penicillin sus-
ceptibility in S. pneumoniae (from 37.3% susceptible
in Hong Kong to 95.0% susceptible in the Nether-
lands) and b-lactamase production in H. influenzae
(from 5% in Italy to 37% France) were found among
the isolates recovered from the study sites in various
countries around the world. These findings, not
unlike those found in other studies, along with
the necessity of empiric treatment of acute respira-
tory infections, underscores the importance of
ongoing surveillance and reporting to keep clinicians
aware of local trends.
Of the agents tested, levofloxacin remains the
most active agent against S. pneumoniae, with 99%
of all isolates and 97.5% of penicillin-resistant
strains susceptible. Amoxicillin and amoxicillin/
clavulanic acid also remain very active against S.
pneumoniae (93.5% susceptible for amoxicillin
and current amoxicillin/clavulanic acid formulation
and 97.3% for enhanced amoxicillin/clavulanic acidformulation), and are the most active oral b-lac-
tams against penicillin-nonsusceptible strains
(100% susceptible for penicillin-intermediate
strains for amoxicillin and both amoxicillin/clavu-
lanic acid formulations; for penicillin-resistant
strains: 60.3% susceptible for amoxicillin and
current amoxicillin/clavulanic acid formulation,
and 83.5% for enhanced amoxicillin/clavulanic
acid formulation). Amoxicillin/clavulanic acid con-
tinues to be very active against b-lactamase-produ-
cing H. influenzae strains (99.6% susceptible). The
percentage of b-lactamase-negative ampicillin-
resistant H. influenzae strains remains extremely
low (0.2%). The majority of M. catarrhalis world-
wide are b-lactamase producers and amoxicillin/
clavulanic acid remains active with all MICs at
2 mg/mL.
Although resistance to the macrolides and dox-
ycycline is evident in several countries, most agents
(including amoxicillin/clavulanic acid) continue to
be very active against S. pyogenes. In other pub-
lished studies, there has been a great deal of inter-
country variation noted in erythromycin resistance
in S. pyogenes, with prevalence in Europe and the
USA ranging from 2—57%.31—33 Italy is consistently
one of the countries with the highest prevalence of
erythromycin-resistant S. pyogenes,34 while many
other European countries and the USA report less
than 10%.
Erythromycin resistance patterns in this study
were consistent with published data: largely a
problem in the European continent (especially
Italy) and Hong Kong.35 The United Kingdom and
the Netherlands, at 100%, and Canada, at 98%,
showed the highest prevalence of erythromycin
susceptibility.
Overall, the most active oral agents against the
common causative agents of community-acquired
respiratory infections found in this study are the
372 L.M. Koeth et al.enhanced formulation of amoxicillin/clavulanic
acid and levofloxacin. The parenteral agent, cef-
triaxone, was also highly effective against these
pathogens. The enhanced formulation of amoxicil-
lin/clavulanic acid also showed excellent activity
against strains resistant to other agents, and is a
valuable addition to the range of oral agents suita-
ble for the treatment of community-acquired
respiratory infections.Acknowledgements
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